Abstract: Aspects of the present disclosure are presented for systems and methods for identifying characteristics of a return pad in a monopolar electrosurgical system using contact quality monitoring (CQM) and near field communication (NFC) signals. In some aspects, resistance or impedance materials are sensed that may help identify what kind of return pad is being used, including what is the structure of the pad. In some aspects, NFC signals are used to identify characteristics of the return pad. In some aspects, the grounding or return pad may include two separate materials that form an interconnecting or interwoven mesh and both act as non-active electrodes when both contact the patient. A non-zero impedance may separate conductive lines connecting the two separate materials that may be analyzed to obtain a defining signature about that is linked to structural characteristics about the return pad.

Abstract: A device may identify a plurality of sources for outputs that the device is configured to provide. The plurality of sources may include at least one of a particular application in the device, an operating system of the device, a particular area within a display of the device, or a particular graphical user interface object. The device may also assign a set of distinct voices to respective sources of the plurality of sources. The device may also receive a request for speech output. The device may also select a particular source that is associated with the requested speech output. The device may also generate speech having particular voice characteristics of a particular voice assigned to the particular source.

Abstract: The invention provides tricyclic compounds that degrade neosubstrates for use in the treatment of disorders described herein, including, for example, abnormal cellular proliferation, neurodegenerative diseases, and autoimmune diseases.

Abstract: A system for growing plants and monitoring the growth of plants, comprising a gardening system and a server. The gardening system comprises a frame that defines a housing for receiving a tray of plants. The gardening system also has a lighting subsystem and watering subsystem to provide light and water to the plants. Sensors and cameras of the gardening system may capture data corresponding to the conditions of the gardening system and health of the plant. Based on the captured data, the server may use machine learning to determine optimal plant growing thresholds, and may send a control command to a controller of the gardening system to change one or more conditions of the gardening system. The plants grown by the system may be nutritious, and the bioavailability of the nutrients of the plants may be increased.

Abstract: The present invention provides an electronic data document (EDD) and related system and method for use in a computerized clinical trial verification system. In an exemplary embodiment, the EDD is authenticated by the creator and validated by the receiver, and comprises an image of a source document (SD) that comprises a masked record of at least one interaction between a clinical trial investigator and a patient enrolled in a clinical trial, at least one revealed portion of the SD that includes evidence relevant to at least one question in a clinical trial questionnaire, and at least one annotation connecting the revealed portion to the at least one question. The present invention provides a computerized system and method for allowing a clinical trial investigator to answer questions from a clinical trial questionnaire pertinent to a clinical trial of a medical treatment using encrypted and partially masked electronic documents comprising images of original patient records.

Abstract: Heterobifunctional compounds for targeted protein degradation that include a tricyclic cereblon binder linked to an appropriate protein targeting ligand to degrade a targeted disease-mediating protein of interest are provided.

Abstract: Pharmaceutical Degraders and Degrons for use in therapeutic applications are described herein.

Abstract: Tricyclic compounds that degrade IKZF2 and/or IKZF4 are provided for medical therapy, including abnormal cellular proliferation, including cancer, inflammatory disorders, neurodegenerative disorders or autoimmune disorders.

Abstract: A device may identify a plurality of sources for outputs that the device is configured to provide. The plurality of sources may include at least one of a particular application in the device, an operating system of the device, a particular area within a display of the device, or a particular graphical user interface object. The device may also assign a set of distinct voices to respective sources of the plurality of sources. The device may also receive a request for speech output. The device may also select a particular source that is associated with the requested speech output. The device may also generate speech having particular voice characteristics of a particular voice assigned to the particular source.

Abstract: A system for growing plants and monitoring the growth of plants, comprising a gardening system and a server. The gardening system comprises a frame that defines a housing for receiving a tray of plants. The gardening system also has a lighting subsystem and watering subsystem to provide light and water to the plants. Sensors and cameras of the gardening system may capture data corresponding to the conditions of the gardening system and health of the plant. Based on the captured data, the server may use machine learning to determine optimal plant growing thresholds, and may send a control command to a controller of the gardening system to change one or more conditions of the gardening system. The plants grown by the system may be nutritious, and the bioavailability of the nutrients of the plants may be increased.

Abstract: The invention provides cereblon binders of Formulas: or pharmaceutically acceptable salts thereof, for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway along with their use in therapeutic applications to treat medical disorders including, but not limited to cancer.

Abstract: This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.

Abstract: Novel compounds which act as protein degradation inducing moieties for proto-oncogene tyrosine-protein kinase receptor (RET), which may be either wild type RET or a mutant form of RET.

Abstract: New treatments for Ikaros and/or Aiolos mediated disorders are provided that comprise administering an effective amount of a cereblon binder that degrades Ikaros or Aiolos by the ubiquitin proteasome pathway.

Abstract: A method and an apparatus for generating a brain break alert is provided. The method includes receiving electroencephalographic (EEG) data of a patient engaged in a cognitive activity at a system server from a user device. The EEG data is captured by electrode of an EEG headset, where the electrode is in physical contact with the patient, and the EEG headset is communicably coupled to the user device. Brain energy used (BEU) by the patient is determined based on the EEG data, brain energy available (BEA) to the patient is determined as a function of the BEU and a predefined initial brain energy (BEI) of the patient, where the BEA is proportional to a difference between the BEI and the BEU, and the BEA satisfying a brain break alert threshold is determined, upon which an instruction to generate a brain break alert (BBA) is sent to the user device.

Abstract: A backwater flow detection device for detecting backwater flow between a building and a sewer conduit using air pressure detection in air pockets in the sewer conduit. The backwater flood detection device detects backwater flow events including backflow events from a sewer line as well as wastewater blockage events that can result in wastewater backflow into a building. The water detection sensor allows the homeowner or building manager to be warned when there is an issue with backwater flow in or near the building, and also with the backwater valve.

Abstract: The present invention provides an electronic data document (EDD) and related system and method for use in a computerized clinical trial verification system. In an exemplary embodiment, the EDD is authenticated by the creator and validated by the receiver, and comprises an image of a source document (SD) that comprises a masked record of at least one interaction between a clinical trial investigator and a patient enrolled in a clinical trial, at least one revealed portion of the SD that includes evidence relevant to at least one question in a clinical trial questionnaire, and at least one annotation connecting the revealed portion to the at least one question. The present invention provides a computerized system and method for allowing a clinical trial investigator to answer questions from a clinical trial questionnaire pertinent to a clinical trial of a medical treatment using encrypted and partially masked electronic documents comprising images of original patient records.

Abstract: This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.

Abstract: Tricyclic cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway for therapeutic applications are described.

Abstract: Compounds of Formula I, Formula II, and Formula III and the pharmaceutically acceptable salts thereof are disclosed. The variables X, a, b, c, d, R1-4, R10-15 and R17-22 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving M2 phenotype of macrophages. Pharmaceutical compositions containing compounds of Formula I or Formula II or Formula III and methods of treatment comprising administering compounds of Formula I and Formula II and Formula III are also disclosed.